QL1203
- Generic Name
- QL1203
Comparing the Pharmacokinetic and Safety of QL1203 and Vectibix® in Healthy Males.
- First Posted Date
- 2020-01-21
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 94
- Registration Number
- NCT04234594
- Locations
- 🇨🇳
Guizhou Cancer Hospital, Guiyang, Guizhou, China
🇨🇳First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety
Phase 3
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 590
- Registration Number
- NCT04233151
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath